Acknowledgements
This research was supported by the National Science and Technology Major Project of the Ministry of Science and Technology of China (No. 2018ZX10301402), the National Natural Science Foundation of China (No. 51973243), the International Cooperation and Exchange of the National Natural Science Foundation of China (No. 51820105004), the Guangdong Innovative and Entrepreneurial Research Team Program (No. 2016ZT06S029), the Guangdong Basic and Applied Basic Research Foundation (No. 2019A1515110903), the Sanming Project of Medicine in Shenzhen (No. SZSM201911004) and the Research Start-up Fund of Post-doctoral, of SAHSYSU (No. ZSQYRSFPD0016).
Footnotes
Wenhao Zhong and Xinyu Zhang contributed equally to this work.
Contributor Information
Dongjun Lin, Email: lindongjun0168@163.com.
Jun Wu, Email: wujun29@mail.sysu.edu.cn.
References
[1] Azarmi S, Roa W H, Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 2008;60:863–875. doi: 10.1016/j.addr.2007.11.006.
[2] Newman S P. Drug delivery to the lungs: Challenges and opportunities. Ther. Deliv. 2017;8:647–661. doi: 10.4155/tde-2017-0037.
[3] Patton J S, Brain J D, Davies L A, Fiegel J, Gumbleton M, Kim K J, Sakagami M, Vanbever R, Ehrhardt C. The particle has landed—characterizing the fate of inhaled pharmaceuticals. J. Aerosol. Med. Pulm. Drug Deliv. 2010;23Suppl2:S71–S87. doi: 10.1089/jamp.2010.0836.
[4] Yu C P. Exact analysis of aerosol deposition during steady breathing. Powder Technol. 1978;27:55–62. doi: 10.1016/0032-5910(78)80107-7.
[5] Bray F, Ferlay J, Soerjomataram I, Siegel R L, Torre L A, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492.
[6] di Sant’Agnese P A, Davis P B. Research in cystic fibrosis (third of three parts) N. Engl. J. Med. 1976;295:597–602. doi: 10.1056/NEJM197609092951105.
[7] Siafakas N M, Vermeire P, Pride N B, Paoletti P, Gibson J, Howard P, Yernault J C, Decramer M, Higenbottam T, Postma D S, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European respiratory society task force. Eur. Respir. J. 1995;8:1398–1420. doi: 10.1183/09031936.95.08081398.
[8] Sevinç F, Prins J M, Koopmans R P, Langendijk P N J, Bossuyt P M, Dankert J, Speelman P. Early switch from intravenous to oral antibiotics: Guidelines and implementation in a large teaching hospital. J. Antimicrob. Chemoth. 1999;43:601–606. doi: 10.1093/jac/43.4.601.
[9] MacGregor R R, Graziani A L. Oral administration of antibiotics: A rational alternative to the parenteral route. Clin. Infect. Dis. 1997;24:457–467. doi: 10.1093/clinids/24.3.457.
[10] Patton J S, Byron P R. Inhaling medicines: Delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007;6:67–74. doi: 10.1038/nrd2153.
[11] Rosen H, Abribat T. The rise and rise of drug delivery. Nat. Rev. Drug Discov. 2005;4:381–385. doi: 10.1038/nrd1721.
[12] Di Marco M, Shamsuddin S, Razak K A, Aziz A A, Devaux C, Borghi E, Levy L, Sadun C. Overview of the main methods used to combine proteins with nanosystems: Absorption, bioconjugation, and encapsulation. Int. J. Nanomedicine. 2010;5:37–49.
[13] Roger E, Lagarce F, Garcion E, Benoit J P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine. 2010;5:287–306. doi: 10.2217/nnm.09.110.
[14] Chao P Y, Deshmukh M, Kutscher H L, Gao D Y, Rajan S S, Hu P D, Laskin D L, Stein S, Sinko P J. Pulmonary targeting microparticulate camptothecin delivery system: Anticancer evaluation in a rat orthotopic lung cancer model. Anti-Cancer Drugs. 2010;27:65–76. doi: 10.1097/CAD.0b013e328332a322.
[15] Patton J S, Fishburn C S, Weers J G. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 2004;1:338–344. doi: 10.1513/pats.200409-049TA.
[16] Sung J C, Pulliam B L, Edwards D A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25:563–570. doi: 10.1016/j.tibtech.2007.09.005.
[17] Dailey L A, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, Kissel T. Nebulization of biodegradable nanoparticles: Impact of nebulizer technology and nanoparticle characteristics on aerosol features. J. Controlled Release. 2003;86:131–144. doi: 10.1016/S0168-3659(02)00370-X.
[18] Geller D E, Pitlick W H, Nardella P A, Tracewell W G, Ramsey B W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002;122:219–226. doi: 10.1378/chest.122.1.219.
[19] Flume P A, VanDevanter D R. Clinical applications of pulmonary delivery of antibiotics. Adv. Drug Deliv. Rev. 2015;85:1–6. doi: 10.1016/j.addr.2014.10.009.
[20] Wenzler E, Fraidenburg D R, Scardina T, Danziger L H. Inhaled antibiotics for gram-negative respiratory infections. Clin. Microbiol. Rev. 2016;29:581–632. doi: 10.1128/CMR.00101-15.
[21] Langton Hewer S C, Smyth A R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database. Syst. Rev. 2017;4:CD004197. doi: 10.1002/14651858.CD004197.pub5.
[22] Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: Strategies that increase life expectancy and improve quality of life. Am. J. Respir. Crit. Care Med. 2011;183:1463–1471. doi: 10.1164/rccm.201009-1478CI.
[23] Mei L, Zhu G Z, Qiu L P, Wu C C, Chen H P, Liang H, Cansiz S, Lv Y F, Zhang X B, Tan W H. Self-assembled multifunctional DNA nanoflowers for the circumvention of multidrug resistance in targeted anticancer drug delivery. Nano Res. 2015;8:3447–3460. doi: 10.1007/s12274-015-0841-8.
[24] Zhou Q, Leung S S Y, Tang P, Parumasivam T, Loh Z H, Chan H K. Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Adv. Drug Deliv. Rev. 2015;85:83–99. doi: 10.1016/j.addr.2014.10.022.
[25] Pérez B F, Méndez G A, Lagos R A, Vargas M S L. Mucociliary clearance system in lung defense. Rev. Med. Chil. 2014;142:606–615. doi: 10.4067/S0034-98872014000500009.
[26] Hardy C L, LeMasurier J S, Mohamud R, Yao J, Xiang S D, Rolland J M, O’Hehir R E, Plebanski M. Differential uptake of nanoparticles and microparticles by pulmonary APC subsets induces discrete immunological imprints. J. Immunol. 2013;191:5278–5290. doi: 10.4049/jimmunol.1203131.
[27] d’Angelo I, Conte C, La Rotonda M I, Miro A, Quaglia F, Ungaro F. Improving the efficacy of inhaled drugs in cystic fibrosis: Challenges and emerging drug delivery strategies. Adv. Drug Deliv. Rev. 2014;75:92–111. doi: 10.1016/j.addr.2014.05.008.
[28] Hoffmann I M, Rubin B K, Iskandar S S, Schechter M S, Nagaraj S K, Bitzan M M. Acute renal failure in cystic fibrosis: Association with inhaled tobramycin therapy. Pediatr. Pulm. 2002;34:375–377. doi: 10.1002/ppul.10185.
[29] Tolker-Nielsen T. Pseudomonas aeruginosa biofilm infections: From molecular biofilm biology to new treatment possibilities. APMIS. 2014;122:1–51. doi: 10.1111/apm.12335.
[30] Allen T M, Cullis P R. Drug delivery systems: Entering the mainstream. Science. 2004;303:1818–1822. doi: 10.1126/science.1095833.
[31] Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature. 2011;469:483–490. doi: 10.1038/nature09657.
[32] Raeburn D, Underwood S L, Villamil M E. Techniques for drug delivery to the airways, and the assessment of lung function in animal models. J. Pharmacol. Toxicol. Methods. 1992;27:143–159. doi: 10.1016/1056-8719(92)90035-Y.
[33] Thompson D C J D. Pharmacology of therapeutic aerosols. Science. 1992;54:29–59.
[34] Courrier H M, Butz N, Vandamme T F. Pulmonary drug delivery systems: Recent developments and prospects. Crit. Rev. Ther. Drug Carrier Syst. 2002;19:425–498. doi: 10.1615/CritRevTherDrugCarrierSyst.v19.i45.40.
[35] Clark A J D D S. Sciences formulation of proteins and peptides for inhalation. Science. 2002;2:73–77.
[36] Gill S, Löbenberg R, Ku T, Azarmi S, Roa W, Prenner E J. Nanoparticles: Characteristics, mechanisms of action, and toxicity in pulmonary drug delivery—a review. J. Biomed. Nanotechnol. 2007;3:107–119. doi: 10.1166/jbn.2007.015.
[37] Ranney D F. Drug targeting to the lungs. Biochem. Pharmacol. 1986;35:1063–1069. doi: 10.1016/0006-2952(86)90140-1.
[38] Barnes P J. Nocturnal asthma: Mechanisms and treatment. Br. Med. J. 1984;288:1397–1398. doi: 10.1136/bmj.288.6428.1397.
[39] Surendrakumar K, Martyn G P, Hodgers E C M, Jansen M, Blair J A. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J. Control. Release. 2003;91:385–394. doi: 10.1016/S0168-3659(03)00263-3.
[40] Cook R O, Pannu R K, Kellaway I W. Novel sustained release microspheres for pulmonary drug delivery. J. Control. Release. 2005;104:79–90. doi: 10.1016/j.jconrel.2005.01.003.
[41] Hardy J G, Chadwick T S. Sustained release drug delivery to the lungs: An option for the future. Clin. Pharmacokinet. 2000;39:1–4. doi: 10.2165/00003088-200039010-00001.
[42] Zeng X M, Martin G P, Marriott C. The controlled delivery of drugs to the lung. Int. J. Pharm. 1995;124:149–164. doi: 10.1016/0378-5173(95)00104-Q.
[43] Bourzac K. Nanotechnology: Carrying drugs. Nature. 2012;491:S58–S60. doi: 10.1038/491S58a.
[44] Pelaz B, Alexiou C, Alvarez-Puebla R A, Alves F, Andrews A M, Ashraf S, Balogh L P, Ballerini L, Bestetti A, Brendel C, et al. Diverse applications of nanomedicine. ACS Nano. 2017;11:2313–2381. doi: 10.1021/acsnano.6b06040.
[45] Vij N. Nano-based rescue of dysfunctional autophagy in chronic obstructive lung diseases. Expert Opin. Drug Deliv. 2017;14:483–489. doi: 10.1080/17425247.2016.1223040.
[46] Zhong W, Zhang X, Zhao M, Wu J, Lin D. Advancements in nanotechnology for the diagnosis and treatment of multiple myeloma. Biomater. Sci. 2020;8:4692–4711. doi: 10.1039/D0BM00772B.
[47] Chen G Y, Roy I, Yang C H, Prasad P N. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem. Rev. 2016;116:2826–2885. doi: 10.1021/acs.chemrev.5b00148.
[48] Singh A P, Biswas A, Shukla A, Maiti P. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct. Target. Ther. 2019;4:33. doi: 10.1038/s41392-019-0068-3.
[49] Xu C C, Li H, Zhang K M, Binzel D W, Yin H R, Chiu W, Guo P X. Photo-controlled release of paclitaxel and model drugs from RNA pyramids. Nano Res. 2019;12:41–48. doi: 10.1007/s12274-018-2174-x.
[50] Ma Q L, Fan Q, Xu J L, Bai J Y, Han X, Dong Z L, Zhou X Z, Liu Z, Gu Z, Wang C. Calming cytokine storm in pneumonia by targeted delivery of TPCA-1 using platelet-derived extracellular vesicles. Matter. 2020;3:287–301. doi: 10.1016/j.matt.2020.05.017.
[51] Zhang X Y, Zhao M Y, Cao N, Qin W, Zhao M, Wu J, Lin D J. Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment. Biomater. Sci. 2020;8:1885–1896. doi: 10.1039/C9BM01927H.
[52] Wagner V, Dullaart A, Bock A K, Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 2006;24:1211–1217. doi: 10.1038/nbt1006-1211.
[53] Stella V J, Nti-Addae K W. Prodrug strategies to overcome poor water solubility. Adv. Drug Deliv. Rev. 2007;59:677–694. doi: 10.1016/j.addr.2007.05.013.
[54] Savjani K T, Gajjar A K, Savjani J K. Drug solubility: Importance and enhancement techniques. Int. Scholar. Res. Not. 2012;2012:195727. doi: 10.5402/2012/195727.
[55] De Jong W H, Borm P J A. Drug delivery and nanoparticles: Applications and hazards. Int. J. Nanomedicine. 2008;3:133–149. doi: 10.2147/IJN.S596.
[56] Zhang L, Pornpattananangkul D, Hu C M J, Huang C M. Development of nanoparticles for antimicrobial drug delivery. Curr. Med. Chem. 2010;17:585–594. doi: 10.2174/092986710790416290.
[57] Murgia X, Loretz B, Hartwig O, Hittinger M, Lehr C M. The role of mucus on drug transport and its potential to affect therapeutic outcomes. Adv. Drug Deliv. Rev. 2018;124:82–97. doi: 10.1016/j.addr.2017.10.009.
[58] Murgia X, Pawelzyk P, Schaefer U F, Wagner C, Willenbacher N, Lehr C M. Size-limited penetration of nanoparticles into porcine respiratory mucus after aerosol deposition. Biomacromolecules. 2016;17:1536–1542. doi: 10.1021/acs.biomac.6b00164.
[59] Ho D K, Costa A, De Rossi C, de Souza Carvalho-Wodarz C, Loretz B, Lehr C M. Polysaccharide submicrocarrier for improved pulmonary delivery of poorly soluble anti-infective ciprofloxacin: Preparation, characterization, and influence of size on cellular uptake. Mol. Pharmaceutics. 2018;15:1081–1096. doi: 10.1021/acs.molpharmaceut.7b00967.
[60] Markman J L, Rekechenetskiy A, Holler E, Ljubimova J Y. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv. Drug Deliv. Rev. 2013;65:1866–1879. doi: 10.1016/j.addr.2013.09.019.
[61] Zhu X, Radovic-Moreno A F, Wu J, Langer R, Shi J J. Nanomedicine in the management of microbial infection —overview and perspectives. Nano Today. 2014;9:478–498. doi: 10.1016/j.nantod.2014.06.003.
[62] Abed N, Couvreur P. Nanocarriers for antibiotics: A promising solution to treat intracellular bacterial infections. Int. J. Antimicrob. Agents. 2014;43:485–496. doi: 10.1016/j.ijantimicag.2014.02.009.
[63] Champion J A, Katare Y K, Mitragotri S. Particle shape: A new design parameter for micro- and nanoscale drug delivery carriers. J. Controlled Release. 2007;121:3–9. doi: 10.1016/j.jconrel.2007.03.022.
[64] Gao W W, Thamphiwatana S, Angsantikul P, Zhang L F. Nanoparticle approaches against bacterial infections. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2014;6:532–547. doi: 10.1002/wnan.1282.
[65] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 2019;69:7–34. doi: 10.3322/caac.21551.
[66] Barenholz Y. Doxil®—the first FDA-approved nano-drug: Lessons learned. J. Control. Release. 2012;160:117–134. doi: 10.1016/j.jconrel.2012.03.020.
[67] Numico G, Castiglione F, Granetto C, Garrone O, Mariani G, Di Costanzo G, La Ciura P, Gasco M, Ostellino O, Porcile G, et al. Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: A pilot trial. Lung Cancer. 2002;35:59–64. doi: 10.1016/S0169-5002(01)00269-0.
[68] Patlakas G, Bouros D, Tsantekidou-Pozova S, Koukourakis M I. Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer. Anticancer Res. 2005;25:1427–1431.
[69] Leighl N B, Goss G D, Lopez P G, Burkes R L, Dancey J E, Rahim Y H, Rudinskas L C, Pouliot J F, Rodgers A, Pond G R, et al. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung Cancer. 2006;52:327–332. doi: 10.1016/j.lungcan.2006.02.006.
[70] Xu C N, Wang Y B, Guo Z P, Chen J, Lin L, Wu J Y, Tian H Y, Chen X S. Pulmonary delivery by exploiting doxorubicin and cisplatin co-loaded nanoparticles for metastatic lung cancer therapy. J. Control. Release. 2019;295:153–163. doi: 10.1016/j.jconrel.2018.12.013.
[71] Hoch U, Staschen C M, Johnson R K, Eldon M A. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother. Pharm. 2014;74:1125–1137. doi: 10.1007/s00280-014-2577-7.
[72] Jameson G S, Hamm J T, Weiss G J, Alemany C, Anthony S, Basche M, Ramanathan R K, Borad M J, Tibes R, Cohn A, et al. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin. Cancer Res. 2013;19:268–278. doi: 10.1158/1078-0432.CCR-12-1201.
[73] Aggarwal C, Cohen R B, Yu E, Hwang W T, Bauml J M, Alley E, Evans T L, Langer C J. Etirinotecan pegol (NKTR-102) in third-line treatment of patients with metastatic or recurrent non-small-cell lung cancer: Results of a phase II study. Clin. Lung Cancer. 2018;19:157–162. doi: 10.1016/j.cllc.2017.10.007.
[74] Zhang H J. Onivyde for the therapy of multiple solid tumors. OncoTargets Ther. 2016;9:3001–3007. doi: 10.2147/OTT.S105587.
[75] Leonard S, Lee H, Klinz S, Paz N, Fitzgerald J, Hendriks B. P1.07-006 Preclinical support for evaluation of irinotecan liposome injection (nal-IRI, MM-398) in small cell lung cancer: Topic: Drug treatment alone and in combination with radiotherapy. J. Thorac. Oncol. 2017;12:S699. doi: 10.1016/j.jtho.2016.11.917.
[76] Landesman-Milo D, Ramishetti S, Peer D. Nanomedicine as an emerging platform for metastatic lung cancer therapy. Cancer Metastasis Rev. 2015;34:291–301. doi: 10.1007/s10555-015-9554-4.
[77] Zhang Y F, Huang Y X, Li S. Polymeric micelles: Nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech. 2014;15:862–871. doi: 10.1208/s12249-014-0113-z.
[78] Gupta N, Hatoum H, Dy G K. First line treatment of advanced non-small-cell lung cancer-specific focus on albumin bound paclitaxel. Int. J. Nanomedicine. 2014;9:209–221. doi: 10.2147/IJN.S41770.
[79] Pazdur R J N C I a t N I o H R A. FDA approval for paclitaxel albumin-stabilized nanoparticle formulation. National Cancer Institute at the National Institutes of Health. 2012;24:2013.
[80] Jiménez-López J, El-Hammadi M M, Ortiz R, Cayero-Otero M D, Cabeza L, Perazzoli G, Martin-Banderas L, Baeyens J M, Prados J, Melguizo C. A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer. Pharmacol. Res. 2019;141:451–465. doi: 10.1016/j.phrs.2019.01.013.
[81] Yang Y, Huang Z W, Li J Y, Mo Z R, Huang Y, Ma C, Wang W H, Pan X, Wu C B. PLGA porous microspheres dry powders for codelivery of afatinib-loaded solid lipid nanoparticles and paclitaxel: Novel therapy for EGFR tyrosine kinase inhibitors resistant nonsmall cell lung cancer. Adv. Healthc. Mater. 2019;8:1900965. doi: 10.1002/adhm.201900965.
[82] Ormerod M G, Orr R M, Peacock J H. The role of apoptosis in cell killing by cisplatin: A flow cytometric study. Br. J. Cancer. 1994;69:93–100. doi: 10.1038/bjc.1994.14.
[83] Sears C R, Cooney S A, Chin-Sinex H, Mendonca M S, Turchi J J. DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer. DNA Rep. 2016;40:35–46. doi: 10.1016/j.dnarep.2016.02.004.
[84] Sun M, He L, Fan Z, Tang R P, Du J Z. Effective treatment of drug-resistant lung cancer via a nanogel capable of reactivating cisplatin and enhancing early apoptosis. Biomaterials. 2020;257:120252. doi: 10.1016/j.biomaterials.2020.120252.
[85] Iyer R, Nguyen T, Padanilam D, Xu C C, Saha D, Nguyen K T, Hong Y. Glutathione-responsive biodegradable polyurethane nanoparticles for lung cancer treatment. J. Control. Release. 2020;321:363–371. doi: 10.1016/j.jconrel.2020.02.021.
[86] Stathopoulos G P, Boulikas T. Lipoplatin formulation review article. J. Drug Deliv. 2012;2012:581363. doi: 10.1155/2012/581363.
[87] Kaltsas K, Anevlavis S, Pataka A, Kouliatsis G, Pozova S, Bouros D, Froudarakis M. A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy. Eur. Respir. Soc. 2016;48:OA3344.
[88] Chan M H, Huang W T, Wang J, Liu R S, Hsiao M. Next-generation cancer-specific hybrid theranostic nanomaterials: MAGE-A3 NIR persistent luminescence nanoparticles conjugated to afatinib for in situ suppression of lung adenocarcinoma growth and metastasis. Adv. Sci. 2020;7:1903741. doi: 10.1002/advs.201903741.
[89] Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–1846. doi: 10.1016/S0140-6736(16)00587-0.
[90] Garon E B, Rizvi N A, Hui R N, Leighl N, Balmanoukian A S, Eder J P, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015;372:2018–2028. doi: 10.1056/NEJMoa1501824.
[91] Liu B, Cao W, Qiao G L, Yao S Y, Pan S J, Wang L R, Yue C X, Ma L J, Liu Y L, Cui D X. Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer. Acta Biomater. 2019;99:307–319. doi: 10.1016/j.actbio.2019.08.046.
[92] Duman F D, Akkoc Y, Demirci G, Bavili N, Kiraz A, Gozuacik D, Acar H Y. Bypassing pro-survival and resistance mechanisms of autophagy in EGFR-positive lung cancer cells by targeted delivery of 5FU using theranostic Ag2S quantum dots. J. Mater. Chem. B. 2019;7:7363–7376. doi: 10.1039/C9TB01602C.
[93] Reda M, Ngamcherdtrakul W, Gu S D, Bejan D S, Siriwon N, Gray J W, Yantasee W. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer. Cancer Lett. 2019;467:9–18. doi: 10.1016/j.canlet.2019.09.014.
[94] Bregoli L, Movia D, Gavigan-Imedio J D, Lysaght J, Reynolds J, Prina-Mello A. Nanomedicine applied to translational oncology: A future perspective on cancer treatment. Nanomedicine. 2016;12:81–103. doi: 10.1016/j.nano.2015.08.006.
[95] Seidi K, Neubauer H A, Moriggl R, Jahanban-Esfahlan R, Javaheri T. Tumor target amplification: Implications for nano drug delivery systems. J. Control. Release. 2018;275:142–161. doi: 10.1016/j.jconrel.2018.02.020.
[96] Chang S S, O’Keefe D S, Bacich D J, Reuter V E, Heston W D W, Gaudin P B. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res. 1999;5:2674–2681.
[97] Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 2012;4:128. doi: 10.1126/scitranslmed.3003651.
[98] Von Hoff D D, Mita M M, Ramanathan R K, Weiss G J, Mita A C, LoRusso P M, Burris H A, III, Hart L L, Low S C, Parsons D M, et al. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin. Cancer Res. 2016;22:3157–3163. doi: 10.1158/1078-0432.CCR-15-2548.
[99] Viteri S, Rosell R. An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs) Transl. Lung Cancer Res. 2018;7:S1–S4. doi: 10.21037/tlcr.2017.12.01.
[100] Reid G, Kao S C, Pavlakis N, Brahmbhatt H, MacDiarmid J, Clarke S, Boyer M, van Zandwijk N. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics. 2016;8:1079–1085. doi: 10.2217/epi-2016-0035.
[101] Kao S C, Fulham M, Wong K, Cooper W, Brahmbhatt H, MacDiarmid J, Pattison S, Sagong J O, Huynh Y, Leslie F, et al. A significant metabolic and radiological response after a novel targeted MicroRNA-based treatment approach in malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 2015;191:1467–1469. doi: 10.1164/rccm.201503-0461LE.
[102] Moro M, Di Paolo D, Milione M, Centonze G, Bornaghi V, Borzi C, Gandellini P, Perri P, Pastorino U, Ponzoni M, et al. Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. J. Control. Release. 2019;308:44–56. doi: 10.1016/j.jconrel.2019.07.006.
[103] Lu C, Stewart D J, Lee J J, Ji L, Ramesh R, Jayachandran G, Nunez M I, Wistuba I I, Erasmus J J, Hicks M E, et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012;7:e34833. doi: 10.1371/journal.pone.0034833.
[104] Sharma S, Srivastava M K, Harris-White M, Lee J M, Dubinett S. MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancer. Expert Opin. Biol. Ther. 2011;11:987–990. doi: 10.1517/14712598.2011.598146.
[105] Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, Cormier Y, Ellis P, Price A, Sawhney R, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 2005;23:6674–6681. doi: 10.1200/JCO.2005.13.011.
[106] Wu Y L, Park K, Soo R A, Sun Y, Tyroller K, Wages D, Ely G, Yang J C H, Mok T. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer. 2011;11:430. doi: 10.1186/1471-2407-11-430.
[107] Griesenbach U, Pytel K M, Alton E W F W. Cystic fibrosis gene therapy in the UK and elsewhere. Hum. Gene Ther. 2015;26:266–275. doi: 10.1089/hum.2015.027.
[108] Hardee C L, Arévalo-Soliz L M, Hornstein B D, Zechiedrich L. Advances in non-viral DNA vectors for gene therapy. Genes. 2017;8:65. doi: 10.3390/genes8020065.
[109] Konstan M W, Davis P B, Wagener J S, Hilliard K A, Stern R C, Milgram L J H, Kowalczyk T H, Hyatt S L, Fink T L, Gedeon C R, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum. Gene Ther. 2004;15:1255–1269. doi: 10.1089/hum.2004.15.1255.
[110] McLachlan G, Davidson H, Holder E, Davies L A, Pringle I A, Sumner-Jones S G, Baker A, Tennant P, Gordon C, Vrettou C, et al. Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung. Gene Ther. 2011;18:996–1005. doi: 10.1038/gt.2011.55.
[111] Alton E W F W, Boyd A C, Cheng S H, Davies J C, Davies L A, Dayan A, Gill D R, Griesenbach U, Higgins T, Hyde S C, et al. Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung. Gene Ther. 2014;21:89–95. doi: 10.1038/gt.2013.61.
[112] Alton E W F W, Baker A, Baker E, Boyd A C, Cheng S H, Coles R L, Collie D D S, Davidson H, Davies J C, Gill D R, et al. The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep. Biomaterials. 2013;34:10267–10277. doi: 10.1016/j.biomaterials.2013.09.023.
[113] Alton E W F W, Boyd A C, Cheng S H, Cunningham S, Davies J C, Gill D R, Griesenbach U, Higgins T, Hyde S C, Innes J A, et al. A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis. Thorax. 2013;68:1075–1077. doi: 10.1136/thoraxjnl-2013-203309.
[114] Alton E W F W, Armstrong D K, Ashby D, Bayfield K J, Bilton D, Bloomfield E V, Boyd A C, Brand J, Buchan R, Calcedo R, et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: A randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Res. Med. 2015;3:684–691. doi: 10.1016/S2213-2600(15)00245-3.
[115] Robinson E, MacDonald K D, Slaughter K, McKinney M, Patel S, Sun C, Sahay G. Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis. Mol. Ther. 2018;26:2034–2046. doi: 10.1016/j.ymthe.2018.05.014.
[116] Haque A K M A, Dewerth A, Antony J S, Riethmüller J, Schweizer G R, Weinmann P, Latifi N, Yasar H, Pedemonte N, Sondo E, et al. Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. Sci. Rep. 2018;8:16776. doi: 10.1038/s41598-018-34960-0.
[117] Tagalakis A D, Munye M M, Ivanova R, Chen H P, Smith C M, Aldossary A M, Rosa L Z, Moulding D, Barnes J L, Kafetzis K N, et al. Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung. Thorax. 2018;73:847–856. doi: 10.1136/thoraxjnl-2017-210670.
[118] Osman G, Rodriguez J, Chan S Y, Chisholm J, Duncan G, Kim N, Tatler A L, Shakesheff K M, Hanes J, Suk J S, et al. PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy. J. Control. Release. 2018;285:35–45. doi: 10.1016/j.jconrel.2018.07.001.
[119] Leal J, Peng X J, Liu X Q, Arasappan D, Wylie D C, Schwartz S H, Fullmer J J, McWilliams B C, Smyth H D C, Ghosh D. Peptides as surface coatings of nanoparticles that penetrate human cystic fibrosis sputum and uniformly distribute in vivo following pulmonary delivery. J. Control. Release. 2020;322:457–469. doi: 10.1016/j.jconrel.2020.03.032.
[120] Garbuzenko O B, Kbah N, Kuzmov A, Pogrebnyak N, Pozharov V, Minko T. Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers. J. Control. Release. 2019;296:225–231. doi: 10.1016/j.jconrel.2019.01.025.
[121] Paranjpe M, Müller-Goymann C C. Nanoparticle-mediated pulmonary drug delivery: A review. Int. J. Mol. Sci. 2014;15:5852–5873. doi: 10.3390/ijms15045852.
[122] Moreno-Sastre M, Pastor M, Salomon C J, Esquisabel A, Pedraz J L. Pulmonary drug delivery: A review on nanocarriers for antibacterial chemotherapy. J. Antimicrob. Chemother. 2015;70:2945–2955. doi: 10.1093/jac/dkv192.
[123] Günday Türeli N, Torge A, Juntke J, Schwarz B C, Schneider-Daum N, Türeli A E, Lehr C M, Schneider M. Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections. Eur. J. Pharm. Biopharm. 2017;117:363–371. doi: 10.1016/j.ejpb.2017.04.032.
[124] Ernst J, Klinger-Strobel M, Arnold K, Thamm J, Hartung A, Pletz M W, Makarewicz O, Fischer D. Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions. Eur. J. Pharm. Biopharm. 2018;131:120–129. doi: 10.1016/j.ejpb.2018.07.025.
[125] Mirza S, Clay R D, Koslow M A, Scanlon P D. COPD guidelines: A Review of the 2018 GOLD Report. Mayo Clin. Proc. 2018;93:1488–1502. doi: 10.1016/j.mayocp.2018.05.026.
[126] da Silva A L, Cruz F F, Rocco P R M, Morales M M. New perspectives in nanotherapeutics for chronic respiratory diseases. Biophys. Rev. 2017;9:793–803. doi: 10.1007/s12551-017-0319-x.
[127] Wu L, Shan W, Zhang Z R, Huang Y. Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties. Adv. Drug Deliv. Rev. 2018;124:150–163. doi: 10.1016/j.addr.2017.10.001.
[128] Ramos F L, Krahnke J S, Kim V. Clinical issues of mucus accumulation in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2014;9:139–150. doi: 10.2147/COPD.S38938.
[129] Zhang X, Zhang W T, Liu L Z, Yang M, Huang L J, Chen K, Wang R, Yang B W, Zhang D D, Wang J L. Antibiotic-loaded MoS2 nanosheets to combat bacterial resistance via biofilm inhibition. Nanotechnology. 2017;28:225101. doi: 10.1088/1361-6528/aa6c9b.
[130] Dua K, Shukla S D, Tekade R K, Hansbro P M. Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases? Drug Deliv. Transl. Res. 2017;7:179–187. doi: 10.1007/s13346-016-0349-0.
[131] Dua K, de Jesus Andreoli Pinto T, Chellappan D K, Gupta G, Bebawy M, Hansbro P M. Advancements in nano drug delivery systems: A challenge for biofilms in respiratory diseases. Panminerva Med. 2018;60:35–36. doi: 10.23736/S0031-0808.18.03402-X.
[132] Mamary A J, Criner G J. Tiotropium bromide for chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2009;3:211–220. doi: 10.1586/ers.09.19.
[133] Quon B S, Goss C H, Ramsey B W. Inhaled antibiotics for lower airway infections. Ann. Am. Thorac. Soc. 2014;11:425–434. doi: 10.1513/AnnalsATS.201311-395FR.
[134] Varshosaz J, Ghaffari S, Mirshojaei S F, Jafarian A, Atyabi F, Kobarfard F, Azarmi S. Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. BioMed Res. Int. 2013;2013:136859. doi: 10.1155/2013/136859.
[135] Kato H, Hagihara M, Hirai J, Sakanashi D, Suematsu H, Nishiyama N, Koizumi Y, Yamagishi Y, Matsuura K, Mikamo H. Evaluation of amikacin pharmacokinetics and pharmacodynamics for optimal initial dosing regimen. Drugs R&D. 2017;17:177–187. doi: 10.1007/s40268-016-0165-5.
[136] Li, Z. B.; Luo, G. H.; Hu, W. P.; Hua, J. L.; Geng, S. Y.; Chu, P. K.; Zhang, J.; Wang, H. Y.; Yu, X. F. Mediated drug release from nanovehicles by black phosphorus quantum dots for efficient therapy of chronic obstructive pulmonary disease. Angew. Chem., Int. Ed. 2020 , doi: 10.1002/anie.202008379.
[137] Chikuma, K.; Arima, K.; Asaba, Y.; Kubota, R.; Asayama, S.; Sato, K.; Kawakami, H. The potential of lipid-polymer nanoparticles as epigenetic and ROS control approaches for COPD. Free Radical Res. 2019 , doi: 10.1080/10715762.2019.1696965.
[138] Mohamed A, Kunda N K, Ross K, Hutcheon G A, Saleem I Y. Polymeric nanoparticles for the delivery of miRNA to treat chronic obstructive pulmonary disease (COPD) Eur. J. Pharm. Biopharm. 2019;136:1–8. doi: 10.1016/j.ejpb.2019.01.002.
[139] Vij N, Min T, Marasigan R, Belcher C N, Mazur S, Ding H, Yong K T, Roy I. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J. Nanobiotechnol. 2010;8:22. doi: 10.1186/1477-3155-8-22.
[140] Roy I, Vij N. Nanodelivery in airway diseases: Challenges and therapeutic applications. Nanomedicine. 2010;6:237–244. doi: 10.1016/j.nano.2009.07.001.
[141] Vij N. Nano-based theranostics for chronic obstructive lung diseases: Challenges and therapeutic potential. Expert. Opin. Drug Deliv. 2011;8:1105–1109. doi: 10.1517/17425247.2011.597381.
[142] Vij N, Min T, Bodas M, Gorde A, Roy I. Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases. Nanomedicine. 2016;12:2415–2427. doi: 10.1016/j.nano.2016.06.008.
[143] Barnes P J, Burney P G J, Silverman E K, Celli B R, Vestbo J, Wedzicha J A, Wouters E F. Chronic obstructive pulmonary disease. Nat. Rev. Dis. Primers. 2015;1:15076. doi: 10.1038/nrdp.2015.76.
[144] Andreeva E, Pokhaznikova M, Lebedev A, Moiseeva I, Kuznetsova O, Degryse J M. Spirometry is not enough to diagnose COPD in epidemiological studies: A follow-up study. Npj Prim. Care Respir. Med. 2017;27:62. doi: 10.1038/s41533-017-0062-6.
[145] Fens N, Zwinderman A H, van der Schee M P, de Nijs S B, Dijkers E, Roldaan A C, Cheung D, Bel E H, Sterk P J. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am. J. Respir. Crit. Care Med. 2009;180:1076–1082. doi: 10.1164/rccm.200906-0939OC.
[146] Dragonieri S, Annema J T, Schot R, van der Schee M P C, Spanevello A, Carratú P, Resta O, Rabe K F, Sterk P J. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer. 2009;64:166–170. doi: 10.1016/j.lungcan.2008.08.008.
[147] Sibila O, Garcia-Bellmunt L, Giner J, Merino J L, Suarez-Cuartin G, Torrego A, Solanes I, Castillo D, Valera J L, Cosio B G, et al. Identification of airway bacterial colonization by an electronic nose in chronic obstructive pulmonary disease. Respir. Med. 2014;108:1608–1614. doi: 10.1016/j.rmed.2014.09.008.
[148] Anusha S C B, Mohan C D, Mathai J, Rangappa S, Mohan S, Chandra, Paricharak S, Mervin L, Fuchs J E, et al. A nano-MgO and ionic liquid-catalyzed ‘green’ synthesis protocol for the development of adamantyl-imidazolo-thiadiazoles as anti-tuberculosis agents targeting sterol 14α-demethylase (CYP51) PLoS One. 2015;10:e0139798. doi: 10.1371/journal.pone.0139798.
[149] Sharma R, Kaur A, Sharma A K, Dilbaghi N, Sharma A K. Nano-based anti-tubercular drug delivery and therapeutic interventions in tuberculosis. Curr. Drug Targets. 2017;18:72–86. doi: 10.2174/1389450116666150804110238.
[150] Nasiruddin M, Neyaz M K, Das S. Nanotechnology-based approach in tuberculosis treatment. Tuberc. Res Treat. 2017;2017:4920209. doi: 10.1155/2017/4920209.
[151] Shojaei T R, Mohd Salleh M A, Tabatabaei M, Ekrami A, Motallebi R, Rahmani-Cherati T, Hajalilou A, Jorfi R. Development of sandwich-form biosensor to detect Mycobacterium tuberculosis complex in clinical sputum specimens. Braz. J. Infect. Dis. 2014;18:600–608. doi: 10.1016/j.bjid.2014.05.015.
[152] Wang S Q, Inci F, De Libero G, Singhal A, Demirci U. Point-of-care assays for tuberculosis: Role of nanotechnology/microfluidics. Biotechnol. Adv. 2013;31:438–449. doi: 10.1016/j.biotechadv.2013.01.006.
[153] Yang H, Qin L H, Wang Y L, Zhang B B, Liu Z H, Ma H, Lu J M, Huang X C, Shi D L, Hu Z Y. Detection of Mycobacterium tuberculosis based on H37Rv binding peptides using surface functionalized magnetic microspheres coupled with quantum dots—a nano detection method for Mycobacterium tuberculosis. Int. J. Nanomed. 2015;10:77–88. doi: 10.2147/IJN.S71700.
[154] Cadena A M, Fortune S M, Flynn J A L. Heterogeneity in tuberculosis. Nat. Rev. Immunol. 2017;17:691–702. doi: 10.1038/nri.2017.69.
[155] Ellis T, Chiappi M, García-Trenco A, Al-Ejji M, Sarkar S, Georgiou T K, Shaffer M S P, Tetley T D, Schwander S, Ryan M P, et al. Multimetallic microparticles increase the potency of rifampicin against intracellular Mycobacterium tuberculosis. ACS Nano. 2018;12:5228–5240. doi: 10.1021/acsnano.7b08264.
[156] Hwang A A, Lee B Y, Clemens D L, Dillon B J, Zink J I, Horwitz M A. pH-responsive isoniazid-loaded nanoparticles markedly improve tuberculosis treatment in Mice. Small. 2015;11:5066–5078. doi: 10.1002/smll.201500937.
[157] Machelart A, Salzano G, Li X, Demars A, Debrie A S, Menendez-Miranda M, Pancani E, Jouny S, Hoffmann E, Deboosere N, et al. Intrinsic antibacterial activity of nanoparticles made of β-cyclodextrins potentiates their effect as drug nanocarriers against tuberculosis. ACS Nano. 2019;13:3992–4007. doi: 10.1021/acsnano.8b07902.
[158] Pi J, Shen L, Yang E Z, Shen H B, Huang D, Wang R, Hu C M, Jin H, Cai H H, Cai J Y, et al. Macrophage-targeted isoniazid-selenium nanoparticles promote antimicrobial immunity and synergize bactericidal destruction of tuberculosis bacilli. Angew. Chem., Int. Ed. 2020;59:3226–3234. doi: 10.1002/anie.201912122.
[159] Welin A, Björnsdottir H, Winther M, Christenson K, Oprea T, Karlsson A, Forsman H, Dahlgren C, Bylund J. CFP-10 from Mycobacterium tuberculosis selectively activates human neutrophils through a pertussis toxin-sensitive chemotactic receptor. Infect. Immun. 2015;83:205–213. doi: 10.1128/IAI.02493-14.
[160] Feng T T, Shou C M, Shen L, Qian Y, Wu Z G, Fan J, Zhang Y Z, Tang Y W, Wu N P, Lu H Z, et al. Novel monoclonal antibodies to ESAT-6 and CFP-10 antigens for ELISA-based diagnosis of pleural tuberculosis. Int. J. Tuberc. Lung Dis. 2011;15:804–810. doi: 10.5588/ijtld.10.0393.
[161] Liu C, Lyon C J, Bu Y, Deng Z A, Walters E, Li Y, Zhang L Q, Hesseling A C, Graviss E A, Hu Y. Clinical evaluation of a blood assay to diagnose paucibacillary tuberculosis via bacterial antigens. Clin. Chem. 2018;64:791–800. doi: 10.1373/clinchem.2017.273698.
[162] Liu C, Zhao Z, Fan J, Lyon C J, Wu H J, Nedelkov D, Zelazny A M, Olivier K N, Cazares L H, Holland S M, et al. Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Prac. Natl. Acad. Sci. USA. 2017;114:3969–3974. doi: 10.1073/pnas.1621360114.
[163] Phan L M T, Rafique R, Baek S H, Nguyen T P, Park K Y, Kim E B, Kim J G, Park J P, Kailasa S K, Kim H J, et al. Gold-copper nanoshell dot-blot immunoassay for naked-eye sensitive detection of tuberculosis specific CFP-10 antigen. Biosens. Bioelectron. 2018;121:111–117. doi: 10.1016/j.bios.2018.08.068.
[164] Meers P, Neville M, Malinin V, Scotto A W, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins W R. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 2008;61:859–868. doi: 10.1093/jac/dkn059.
[165] Ehsan Z, Clancy J P. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. Future Microbiol. 2015;10:1901–1912. doi: 10.2217/fmb.15.117.
[166] Waters V, Ratjen F. Inhaled liposomal amikacin. Expert Rev. Respir. Med. 2014;8:401–409. doi: 10.1586/17476348.2014.918507.
[167] Costa-Gouveia J, Pancani E, Jouny S, Machelart A, Delorme V, Salzano G, Iantomasi R, Piveteau C, Queval C J, Song O R, et al. Combination therapy for tuberculosis treatment: Pulmonary administration of ethionamide and booster co-loaded nanoparticles. Sci. Rep. 2017;7:5390. doi: 10.1038/s41598-017-05453-3.
[168] Serisier D J, Bilton D, De Soyza A, Thompson P J, Kolbe J, Greville H W, Cipolla D, Bruinenberg P, Gonda I. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): A randomised, double-blind, placebo-controlled trial. Thorax. 2013;68:812–817. doi: 10.1136/thoraxjnl-2013-203207.
[169] Doroudian M, MacLoughlin R, Poynton F, Prina-Mello A, Donnelly S C. Nanotechnology based therapeutics for lung disease. Thorax. 2019;74:965–976. doi: 10.1136/thoraxjnl-2019-213037.
[170] Hamblin K A, Wong J P, Blanchard J D, Atkins H S. The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy. Front. Cell. Infect. Microbiol. 2014;4:79. doi: 10.3389/fcimb.2014.00079.
[171] Wong J P, Yang H M, Blasetti K L, Schnell G, Conley J, Schofield L N. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Release. 2003;92:265–273. doi: 10.1016/S0168-3659(03)00358-4.
[172] Haworth C, Wanner A, Froehlich J, O’Neal T, Davis A, Gonda I, O’Donnell A. Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection: Results from two parallel phase III trials (ORBIT-3 and-4) Am. J. Respir. Crit. Care Med. 2017;195:A7604.
[173] Ho D K, Murgia X, De Rossi C, Christmann R, Hüfner de Mello Martins A G, Koch M, Andreas A, Herrmann J, Müller R, Empting M, et al. Squalenyl hydrogen sulfate nanoparticles for simultaneous delivery of tobramycin and an alkylquinolone quorum sensing inhibitor enable the eradication of P. aeruginosa biofilm infections. Angew. Chem., Int. Ed. 2020;59:10292–10296. doi: 10.1002/anie.202001407.
[174] Gao Y F, Wang J, Chai M Y, Li X, Deng Y Y, Jin Q, Ji J. Size and charge adaptive clustered nanoparticles targeting the biofilm microenvironment for chronic lung infection management. ACS Nano. 2020;14:5686–5699. doi: 10.1021/acsnano.0c00269.
[175] Wang Y, Yuan Q, Feng W, Pu W D, Ding J, Zhang H J, Li X Y, Yang B, Dai Q, Cheng L, et al. Targeted delivery of antibiotics to the infected pulmonary tissues using ROS-responsive nanoparticles. J. Nanobiotechnol. 2019;17:103. doi: 10.1186/s12951-019-0537-4.
[176] Zhang C Y, Lin W J, Gao J, Shi X T, Davaritouchaee M, Nielsen A E, Mancini R J, Wang Z J. pH-responsive nanoparticles targeted to lungs for improved therapy of acute lung inflammation/injury. ACS Appl. Mater. Interfaces. 2019;11:16380–16390. doi: 10.1021/acsami.9b04051.
[177] Shirkhani K, Teo I, Armstrong-James D, Shaunak S. Nebulised amphotericin B-polymethacrylic acid nanoparticle prophylaxis prevents invasive aspergillosis. Nanomedicine. 2015;11:1217–1226. doi: 10.1016/j.nano.2015.02.012.
[178] Tang Y X, Wu S, Lin J Q, Cheng L T, Zhou J, Xie J, Huang K X, Wang X Y, Yu Y, Chen Z B, et al. Nanoparticles targeted against cryptococcal pneumonia by interactions between chitosan and its peptide ligand. Nano Lett. 2018;18:6207–6213. doi: 10.1021/acs.nanolett.8b02229.
[179] Qiu L X, Hu B C, Chen H B, Li S S, Hu Y Q, Zheng Y, Wu X X. Antifungal efficacy of itraconazole-loaded TPGS-b-(PCL-ran-PGA) nanoparticles. Int. J. Nanomedicine. 2015;10:1415–1423. doi: 10.2147/IJN.S71616.
[180] Wang J, Li P Y, Yu Y, Fu Y H, Jiang H Y, Lu M, Sun Z P, Jiang S B, Lu L, Wu M X. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science. 2020;367:eaau0810. doi: 10.1126/science.aau0810.
[181] Sanchez-Guzman D, Le Guen P, Villeret B, Sola N, Le Borgne R, Guyard A, Kemmel A, Crestani B, Sallenave J M, Garcia-Verdugo I. Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity. Biomaterials. 2019;217:119308. doi: 10.1016/j.biomaterials.2019.119308.
[182] Kim H, Park M, Hwang J, Kim J H, Chung D R, Lee K S, Kang M. Development of label-free colorimetric assay for MERS-CoV using gold nanoparticles. ACS Sens. 2019;4:1306–1312. doi: 10.1021/acssensors.9b00175.
[183] Layqah L A, Eissa S. An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes. Microchim. Acta. 2019;186:224. doi: 10.1007/s00604-019-3345-5.
[184] Holgate S T, Wenzel S, Postma D S, Weiss S T, Renz H, Sly P D. Asthma. Nat. Rev. Dis. Primers. 2015;1:15025. doi: 10.1038/nrdp.2015.25.
[185] Huang C L, Wang Y M, Li X W, Ren L L, Zhao J P, Hu Y, Zhang L, Fan G H, Xu J Y, Gu X Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
[186] Wang D W, Hu B, Hu C, Zhu F F, Liu X, Zhang J, Wang B B, Xiang H, Cheng Z S, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585.
[187] Zhou P, Yang X L, Wang X G, Hu B, Zhang L, Zhang W, Si H R, Zhu Y, Li B, Huang C L, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7.
[188] Zhu N, Zhang D Y, Wang W L, Li X W, Yang B, Song J D, Zhao X, Huang B Y, Shi W F, Lu R J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017.
[189] Wu F, Zhao S, Yu B, Chen Y M, Wang W, Song Z G, Hu Y, Tao Z W, Tian J H, Pei Y Y, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269. doi: 10.1038/s41586-020-2008-3.
[190] Udugama B, Kadhiresan P, Kozlowski H N, Malekjahani A, Osborne M, Li V Y C, Chen H M, Mubareka S, Gubbay J B, Chan W C W. Diagnosing COVID-19: The disease and tools for detection. ACS nano. 2020;14:3822–3835. doi: 10.1021/acsnano.0c02624.
[191] Moitra P, Alafeef M, Dighe K, Frieman M B, Pan D. Selective naked-eye detection of SARS-CoV-2 mediated by n gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS Nano. 2020;14:7617–7627. doi: 10.1021/acsnano.0c03822.
[192] Chen Z H, Zhang Z G, Zhai X M, Li Y Y, Lin L, Zhao H, Bian L, Li P, Yu L, Wu Y S, et al. Rapid and sensitive detection of anti-SARS-CoV-2 IgG, using lanthanide-doped nanoparticles-based lateral flow immunoassay. Anal. Chem. 2020;92:7226–7231. doi: 10.1021/acs.analchem.0c00784.
[193] Yadavalli T, Shukla D. Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections. Nanomedicine. 2017;13:219–230. doi: 10.1016/j.nano.2016.08.016.
[194] Quesada-González D, Merkoçi A. Nanomaterial-based devices for point-of-care diagnostic applications. Chem. Soc. Rev. 2018;47:4697–4709. doi: 10.1039/C7CS00837F.
[195] Maltez-da Costa M, de la Escosura-Muñiz A, Nogués C, Barrios L, Ibáñez E, Merkoçi A. Simple monitoring of cancer cells using nanoparticles. Nano Lett. 2012;12:4164–4171. doi: 10.1021/nl301726g.
[196] Seo G, Lee G, Kim M J, Baek S H, Choi M, Ku K B, Lee C S, Jun S, Park D, Kim H G, et al. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano. 2020;14:5135–5142. doi: 10.1021/acsnano.0c02823.
[197] Szunerits S, Barras A, Khanal M, Pagneux Q, Boukherroub R. Nanostructures for the inhibition of viral infections. Molecules. 2015;20:14051–14081. doi: 10.3390/molecules200814051.
[198] Fahmi M Z, Sukmayani W, Khairunisa S Q, Witaningrum A M, Indriati D W, Matondang M Q Y, Chang J Y, Kotaki T, Kameoka M. Design of boronic acid-attributed carbon dots on inhibits HIV-1 entry. RSC Adv. 2016;6:92996–93002. doi: 10.1039/C6RA21062G.
[199] Łoczechin A, Séron K, Barras A, Giovanelli E, Belouzard S, Chen Y T, Metzler-Nolte N, Boukherroub R, Dubuisson J, Szunerits S. Functional carbon quantum dots as medical countermeasures to human coronavirus. ACS Appl. Mater. Interfaces. 2019;11:42964–42974. doi: 10.1021/acsami.9b15032.
[200] Yuan Y, Cao D F, Zhang Y F, Ma J, Qi J X, Wang Q H, Lu G W, Wu Y, Yan J H, Shi Y, et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun. 2017;8:15092. doi: 10.1038/ncomms15092.
[201] Raj V S, Mou H, Smits S L, Dekkers D H W, Müller M A, Dijkman R, Muth D, Demmers J A A, Zaki A, Fouchier R A M, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495:251–254. doi: 10.1038/nature12005.
[202] Coleman C M, Venkataraman T, Liu Y V, Glenn G M, Smith G E, Flyer D C, Frieman M B. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine. 2017;35:1586–1589. doi: 10.1016/j.vaccine.2017.02.012.
[203] Shereen M A, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J. Adv. Res. 2020;24:91–98. doi: 10.1016/j.jare.2020.03.005.
[204] Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer R A, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905–913. doi: 10.1016/j.cell.2020.04.004.
[205] Zhang H B, Penninger J M, Li Y M, Zhong N S, Slutsky A S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intens. Care Med. 2020;46:586–590. doi: 10.1007/s00134-020-05985-9.
[206] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens T S, Herrler G, Wu N H, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280. doi: 10.1016/j.cell.2020.02.052.
[207] Singh L, Kruger H G, Maguire G E M, Govender T, Parboosing R. The role of nanotechnology in the treatment of viral infections. Ther. Adv. Infect. Dis. 2017;4:105–131. doi: 10.1177/2049936117713593.
[208] Jackman J A, Lee J, Cho N J. Nanomedicine for infectious disease applications: Innovation towards broad-spectrum treatment of viral infections. Small. 2016;12:1133–1139. doi: 10.1002/smll.201500854.
[209] Adesina S K, Akala E O. Nanotechnology approaches for the delivery of exogenous siRNA for HIV therapy. Mol. Pharmaceutics. 2015;12:4175–4187. doi: 10.1021/acs.molpharmaceut.5b00335.
[210] Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M, Savory E, Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–e31. doi: 10.1016/S0140-6736(20)30304-4.
[211] Pu S Y, Xiao F, Schor S, Bekerman E, Zanini F, Barouch-Bentov R, Nagamine C M, Einav S. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral. Res. 2018;155:67–75. doi: 10.1016/j.antiviral.2018.05.001.
[212] Chen N S, Zhou M, Dong X, Qu J M, Gong F Y, Han Y, Qiu Y, Wang J L, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7.
[213] Xu H P, He C Y, Liu Y, Jiang J L, Ma T. Novel therapeutic modalities and drug delivery-erlotinib liposomes modified with galactosylated lipid: In vitro and in vivo investigations. Artif. Cells Nanomed. Biotechnol. 2018;46:1902–1907. doi: 10.1080/21691401.2017.1396222.
[214] Zeng, C. X.; Hou, X. C.; Yan, J. Y.; Zhang, C. X.; Li, W. Q.; Zhao, W. Y.; Du, S.; Dong, Y. Z. Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivo. bioRxiv 2020 , doi: 10.1101/2020.04.01.019877.
[215] Broza Y Y, Haick H. Nanomaterial-based sensors for detection of disease by volatile organic compounds. Nanomedicine. 2013;8:785–806. doi: 10.2217/nnm.13.64.
[216] Dragonieri S, Schot R, Mertens B J A, Le Cessie S, Gauw S A, Spanevello A, Resta O, Willard N P, Vink T J, Rabe K F, et al. An electronic nose in the discrimination of patients with asthma and controls. J. Allergy Clin. Immunol. 2007;120:856–862. doi: 10.1016/j.jaci.2007.05.043.
[217] Taylor S L, Leong L E X, Choo J M, Wesselingh S, Yang I A, Upham J W, Reynolds P N, Hodge S, James A L, Jenkins C, et al. Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology. J. Allergy Clin. Immunol. 2018;141:94–103. doi: 10.1016/j.jaci.2017.03.044.
[218] Plaza V, Crespo A, Giner J, Merino J L, Ramos-Barbón D, Mateus E F, Torrego A, Cosio B G, Agustí A, Sibila O. Inflammatory asthma phenotype discrimination using an electronic nose breath analyzer. J. Investig. Allergol. Clin. Immunol. 2015;25:431–437.
[219] Keil T W M, Feldmann D P, Costabile G, Zhong Q, da Rocha S, Merkel O M. Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles. Eur. J. Pharm. Biopharm. 2019;143:61–69. doi: 10.1016/j.ejpb.2019.08.012.
[220] Bhavna, Ahmad F J, Mittal G, Jain G K, Malhotra G, Khar R K, Bhatnagar A. Nano-salbutamol dry powder inhalation: A new approach for treating broncho-constrictive conditions. Eur. J. Pharm. Biopharm. 2009;71:282–291. doi: 10.1016/j.ejpb.2008.09.018.
[221] Matsuo Y, Ishihara T, Ishizaki J, Miyamoto K I, Higaki M, Yamashita N. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell. Immunol. 2009;260:33–38. doi: 10.1016/j.cellimm.2009.07.004.
[222] Nasr M, Najlah M, D’Emanuele A, Elhissi A. PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization. Int. J. Pharmaceut. 2014;461:242–250. doi: 10.1016/j.ijpharm.2013.11.023.
[223] Kenyon N J, Bratt J M, Lee J, Luo J T, Franzi L M, Zeki A A, Lam K S. Self-assembling nanoparticles containing dexamethasone as a novel therapy in allergic airways inflammation. PLoS One. 2013;8:e77730. doi: 10.1371/journal.pone.0077730.
[224] Chen X Y, Huang W H, Wong B C, Yin L L, Wong Y F, Xu M, Yang Z J. Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int. J. Nanomedicine. 2012;7:1139–1148. doi: 10.2147/IJN.S28011.
[225] Arafa M G, Ayoub B M. Nano-vesicles of salbutamol sulphate in metered dose inhalers: Formulation, characterization and in vitro evaluation. Int. J. Appl. Pharmaceut. 2017;9:100–105. doi: 10.22159/ijap.2017v9i6.22448.
[226] Wang K, Feng Y P, Li S, Li W J, Chen X, Yi R, Zhang H R, Hong Z Y. Oral delivery of bavachinin-loaded PEG-PLGA nanoparticles for asthma treatment in a murine model. J. Biomed. Nanotechnol. 2018;14:1806–1815. doi: 10.1166/jbn.2018.2618.
[227] Chakraborty S, Ehsan I, Mukherjee B, Mondal L, Roy S, Saha K D, Paul B, Debnath M C, Bera T. Therapeutic potential of andrographolide-loaded nanoparticles on a murine asthma model. Nanomedicine. 2019;20:102006. doi: 10.1016/j.nano.2019.04.009.
[228] Joshi V B, Adamcakova-Dodd A, Jing X F, Wongrakpanich A, Gibson-Corley K N, Thorne P S, Salem A K. Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy. AAPS J. 2014;16:975–985. doi: 10.1208/s12248-014-9624-5.
[229] Salem A K. A promising CpG adjuvant-loaded nanoparticle-based vaccine for treatment of dust mite allergies. Immunotherapy. 2014;6:1161–1163. doi: 10.2217/imt.14.97.
[230] Grozdanovic M, Laffey K G, Abdelkarim H, Hitchinson B, Harijith A, Moon H G, Park G Y, Rousslang L K, Masterson J C, Furuta G T, et al. Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness. J. Allergy Clin. Immunol. 2019;143:669–680. doi: 10.1016/j.jaci.2018.05.003.
[231] Kumar M, Kong X Y, Behera A K, Hellermann G R, Lockey R F, Mohapatra S S. Chitosan IFN- γ -pDNA nanoparticle (CIN) therapy for allergic asthma. Genet. Vaccines Ther. 2003;1:3. doi: 10.1186/1479-0556-1-3.
[232] Kong X Y, Hellermann G R, Zhang W D, Jena P, Kumar M, Behera A, Behera S, Lockey R, Mohapatra S S. Chitosan interferon-γ nanogene therapy for lung disease: Modulation of T-cell and dendritic cell immune responses. Allergy Asthma Clin. Immnuol. 2008;4:95–105. doi: 10.1186/1710-1492-4-3-95.
[233] Farokhzad O C, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3:16–20. doi: 10.1021/nn900002m.
[234] Shi J J, Votruba A R, Farokhzad O C, Langer R. Nanotechnology in drug delivery and tissue engineering: From discovery to applications. Nano Lett. 2010;10:3223–3230. doi: 10.1021/nl102184c.
[235] Sanhai W R, Sakamoto J H, Canady R, Ferrari M. Seven challenges for nanomedicine. Nat. Nanotechnol. 2008;3:242–244. doi: 10.1038/nnano.2008.114.
[236] Sanders N, Rudolph C, Braeckmans K, De Smedt S C, Demeester J. Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev. 2009;61:115–127. doi: 10.1016/j.addr.2008.09.011.
[237] Lai S K, Wang Y Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009;61:158–171. doi: 10.1016/j.addr.2008.11.002.
[238] Lai S K, Wang Y Y, Wirtz D, Hanes J. Micro- and macrorheology of mucus. Adv. Drug Deliv. Rev. 2009;61:86–100. doi: 10.1016/j.addr.2008.09.012.
[239] Petros R A, DeSimone J M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010;9:615–627. doi: 10.1038/nrd2591.
[240] Dobrovolskaia M A, McNeil S E. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007;2:469–478. doi: 10.1038/nnano.2007.223.
[241] Schuster B S, Suk J S, Woodworth G F, Hanes J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials. 2013;34:3439–3446. doi: 10.1016/j.biomaterials.2013.01.064.
[242] Huckaby J T, Lai S K. PEGylation for enhancing nanoparticle diffusion in mucus. Adv. Drug Deliv. Rev. 2018;124:125–139. doi: 10.1016/j.addr.2017.08.010.
[243] Shi J J, Kantoff P W, Wooster R, Farokhzad O C. Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer. 2017;17:20–37. doi: 10.1038/nrc.2016.108.
[244] Hare J I, Lammers T, Ashford M B, Puri S, Storm G, Barry S T. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv. Drug Deliv. Rev. 2017;108:25–38. doi: 10.1016/j.addr.2016.04.025.
[245] Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J. Control. Release. 2015;219:500–518. doi: 10.1016/j.jconrel.2015.07.024.
[246] Hossen S, Hossain M K, Basher M K, Mia M N H, Rahman M T, Uddin M J. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. J. Adv. Res. 2019;15:1–18. doi: 10.1016/j.jare.2018.06.005.
[247] Wilhelm S, Tavares A J, Dai Q, Ohta S, Audet J, Dvorak H F, Chan W C W. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 2016;1:16014. doi: 10.1038/natrevmats.2016.14.
[248] Genchi G G, Marino A, Tapeinos C, Ciofani G. Smart materials meet multifunctional biomedical devices: Current and prospective implications for nanomedicine. Front. Bioeng. Biotechnol. 2017;5:80. doi: 10.3389/fbioe.2017.00080.